학술논문

Non-alcoholic Fatty liver Disease in Patients with Psoriasis - Therapeutic Implications
Document Type
article
Source
Advances in Dermatology and Allergology, Vol 37, Iss 4, Pp 468-474 (2019)
Subject
psoriasis
liver disease
methotrexate
biologic agents.
Dermatology
RL1-803
Internal medicine
RC31-1245
Language
English
ISSN
1642-395X
2299-0046
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common liver pathology in the West. Psoriatic patients are at higher risk of having NAFLD, and at higher risk of experiencing the more severe form of the disease, with poorer outcomes. The components of the metabolic syndrome – obesity, lipid abnormalities, hypertension, and type 2 diabetes – significantly correlate with NAFLD progression. The inflammatory state present in psoriasis plays a significant role in development of NAFLD and the metabolic syndrome. All patients with psoriasis and insulin resistance and risk factors for metabolic syndrome should also been screened for NAFLD, and planning of the treatment options should always take into consideration the possible risks for the liver, especially in patients with NAFLD.